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Abstract 
Purpose: To investigate the clinical benefits and underlying mechanisms of action of betulin in the 
treatment of cancer using a neuroblastoma (NB) cell model.  
Method: Cell viability assay (MTT assay) was applied to investigate the effects of betulin on 
proliferation and apoptosis of SK-N-SH cell. The expression or translocation of apoptosis-related 
biomarkers, which include protein kinase C (PKC) family members, were analyzed and quantified by 
Western blotting, caspase activity assay or enzyme-linked immunosorbent assay (ELISA). 
Results: Betulin treatment significantly inhibited the growth of SK-N-SH cells (p < 0.001), with half-
maximal inhibition concentration (IC50) of 8 μmol/mL. Furthermore, betulin treatment increased the 
activity of PKC-δ, which subsequently activated caspases 3, 8 and 9, thus initiating mitochondria-
mediated endogenous apoptotic pathways in SK-N-SH cells    
Conclusion: Data generated in this study suggest that betulin inhibits cell proliferation and promotes 
apoptosis via PKC-δ activation, which may provide new insights into NB treatment from the perspective 
of adjuvant chemotherapy and prevention of tumor recurrence. 
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Neuroblastoma (NB) is a type of pediatric extra-
cranial solid cancer, which occurs during the 
development of sympathetic nerves [1]. It is 
highly prevalent in infants and children, with an 
average death rate of 15 % globally, accounting 
for 7 % of all malignant tumors diagnosed in 
children (under 14 years old) [2-4]. The 
international NB staging system categorized NB 
into five stages: stages 1 to 4, and a special 
stage 4+ [5]. Stage 3 and stage 4/4+ are 
identified as the late stage, during which the 
disease progression deteriorates rapidly [6]. In 
the late stage, NB cells migrate to multiple 
tissues, including bone marrow, bone, lymph 
nodes, liver and intracranial region [2,7]. The 
long-term survival rate in the late-stage patients 
is less than 40 % even with increasing doses of 
drug [8].Therefore, there is the urgent need to 
find natural drug candidates that can inhibit the 
growth of NB without adverse effect on healthy 
tissues. Such agents should qualify for use as 
adjuvant agents during chemotherapy and 
prognosis. 
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Betulin was first discovered and purified from the 
bark of Betula platyphlla [9]. It is a triterpenoid 
compound which exerts remarkable anti-
bacterial, anti-fungal, anti-viral, anti-inflammatory 
and especially anti-cancer activities [10-12]. 
Available evidence indicate that betulin could 
induce apoptosis and inhibit the growth of tumor 
cells, and yet exhibit little toxic effects on normal 
cells [13-18]. Evidently, betulin because of its 
unique ability to discriminate tumor cells from 
healthy cells, is a natural therapeutic agent which 
should be further explored in vitro as an anti-
cancer drug in pre-clinical and clinical trials. 
 
Protein kinase C (PKC) belongs to a class of 
serine/threonine protein kinases that regulate 
differentiation, migration, proliferation, and 
apoptosis by catalyzing the phosphorylation of 
serine or threonine residue [19]. According to 
their second messenger requirements, PKC can 
be divided into three sub-families: classic PKC (c 
PKC), new PKC (n PKC) and non-classical PKC 
(a PKC). PKC-δ belongs to nPKC sub-family 
which is composed of an N-terminal regulatory 
region and a C-terminal catalytic domain. 
Activation of PKC-δ requires diacylglycerol 
(DAG) and phorbol ester (PMA), but not calcium 
ions. Activated PKC-δ regulates cell death and 
cell survival via phosphorylation/de-
phosphorylation [23,24]. Known as type I 
programmed cell death, apoptosis is highly 
controlled process, functioning as one of the 
major anti-cancer mechanisms.  
 
This study was aimed at investigating if betulin 
inhibits the proliferation of neuroblastoma SK-N-
SH cells by activating endogenous apoptosis. In 
addition, the effect of botulin on the upstream of 






Human neuroblastoma SK-N-SH cells were gifts 
from Department of Oncology, First Hospital of 
Jilin University (Jilin, China). SK-N-SH cells were 
cultured in RPMI-1640 medium, supplemented 
with 10% fetal bovine serum (FBS) at 37 °C in a 




Transfection was performed via LipofectAmine 
2000 (Invitrogen). LipofectAmine 2000 was 
mixed with serum-free RPMI-1640 at 22 OC for 5 
min, and then co-incubated with plasmid DNA or 
shRNA for 25 min. Lipid-DNA complex was 
added to SK-N-SH cells and incubated for 24 h 
for further transfection. 
Reagents and materials 
 
Betulin, PMA, MTT, HRP labeled goat anti-rabbit 
antibody, rabbit anti-mouse and rabbit anti-goat 
antibodies were purchased from Sigma (St. 
Louis, USA). Z-VAD-FMK, GF109203X were 
purchased from Selleck (Houston, USA); RPMI-
1640 medium and Gibco fetal bovine serum were 
purchased from Invitrogen (Carlsbad, USA); 
Caspase assay reagent was obtained from 
Calbiochem (La Jolla, USA), while mitochondrial 
extraction kit, BCA protein assay kit, and ultra-
sensitive ECL chemiluminescence kit were 
products of Beyotime (Shanghai, China). PKC 
activity test kit was purchased from Abcam 
(Cambridge, England).  
 
Primary rabbit anti-PARP, mouse anti-
cytochrome c, rabbit anti-SMAC, rabbit anti-COX 
IV, rabbit anti-CD95 and mouse anti-β-Actin were 
products of Abcam (Cambridge, England). Rabbit 
anti-Bax, rabbit anti-TNF-R2 and rabbit anti-Bak 
were purchased from CST (Danfoss, USA), while 
primary rabbit anti-DR4, rabbit anti-DR5, rabbit 
anti-PKC-α, mouse anti-PKC-ζ, and rabbit anti-
PKC-δ were supplied by Santa Cruz (California, 
USA). pGPU6 –Neo-PKCδ plasmid was obtained 
from GenePharma (Jiangsu China). pcDNA3.1 
(+)-PKC-δ-CF plasmid was a gift from First 
Hospital of Jilin University. Full-featured 
microplate reader (Synergy H1) was purchased 




Cells were seeded in 96-well plates at 104 cells 
per well. Following 20-h seeding, the cells were 
treated with betulin at different concentrations (0, 
2.5, 5, 7.5, 10, 12.5 and 15 uM ) for 46 h, and 20 
μL of 5 mg/mL MTT was subsequently added to 
each medium, and left to incubate for 2 h at 37 
°C. Then, the medium was discarded and 150 μL 
DMSO was added into each well. The 
absorbance of the samples was measured at 550 
nm using BioTek Synergy H1. 
 
Western blot analysis 
 
Protein concentrations of samples were 
measured by BCA assay. Samples were 
resolved by SDS-polyacrylamide gels. Proteins 
from SDS-PAGE were transferred onto 
nitrocellulose membranes. Membranes were 
incubated in blocking buffer (5 % milk in PBST 
with 0.1 % Tween-20) for 1 h; After PBS-Tween 
buffer wash, membranes were incubated with 
primary antibody (1:1000 dilution) in blocking 
buffer (3 % milk in PBST with 1 % of sodium 
azide) for 3 h at room temperature or at 4 OC 
overnight .followed by 1 h incubation with 
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appropriate secondary antibody-HRP at room 
temperature. Detection was carried out with 
enhanced chemiluminescence using ECL 
reagent kit. 
 
Caspase activity assay  
 
Total cell lysate (100 μg) and 200 μL reaction 
buffer were co-incubated at 37 oC for 1 h. The 
fluorescent intensity was measured at 405nm 
(excitation) and 505 nm (emission). Two hundred 
microliters of reaction buffer and 100 μl lysis 
buffer were used as negative control. The 
reaction buffer (20 mM HEPES, pH 7.4) 
contained 100 mM NaCl, 10 mM DTT, 0.1 % 
CHAPS, 10 % sucrose and 25 μM caspase 
substrates. 
 
Isolation of mitochondria 
 
Mitochondria extraction was performed following 
the extraction kit protocol. SK-N-SH cells in 
logarithmic growth phase were trypsinised and 
centrifuged. Cell pellets were washed and re-
suspended in mito-separation buffer on ice. Cell 
lysates were subsequently homogenized and 
centrifuged at 600 x g for 10 min. The 
supernatant was transferred in appropriate 
centrifuge tubes and further centrifuged at 11000 
x g for 10 min. The pellet (mitochondria) was 
separated from the supernatant and then re-
suspended in storage buffer. 
 
Assay of PKC activity  
 
PKC activity was assayed by ELISA. SK-N-SH 
cell pellets were re-suspended in lysis buffer [(20 
mM propanesulfonic acid (MOPS), Ethylene 
glycol-bis (oxyethylenenitrilo) tetraacetic acid 
(EGTA, 5 mM) and 2 mM ethylene diamine 
tetraacetic acid (EDTA), 1 % Nonidet P40 
(NP40), 50 mM β-glycerophosphate, 50 mM 
sodium fluoride, 1mM sodium vanadate, 1 mM 
dithiothreitol and 1mM Benzamidine, 1 mM 
PMSF and 10 μg/mL leupeptin and aprotinin)] on 
ice for 10 min, followed by centrifugation at 
12000 rpm for 20 min at 4 oC.  
 
Fifteen micrograms of protein from each sample 
was used for ELISA. Cell lysate was first 
incubated with 40 μL primary antibody for 1h and 
subsequently with an HRP-conjugated secondary 
antibody (1: 1000) for 20 min. Lysate-antibody 
mixtures were incubated with 60 uL TMB 
substrates for 45 min and then mixed with the 
stop buffer. The absorbance of each sample was 




Data are presented as mean ± standard 
deviation (SD). Statistical analysis was 
performed using unpaired two-sample t-test, with 





Effect of betulin on SK-N-SH cell viability  
 
To explore the effects of betulin treatments on 
SK-N-SH cells, changes in viability and the 
apoptotic cell death-related biomarkers in cells 
were monitored following betulin treatments. With 
increasing betulin concentration, SK-N-SH cell 
viability gradually decreased in a dose-
dependent manner, with an IC50 at approximately 
8PP μmol /mL (Figure 1A). At 10 μmol/mL 
betulin, cell viability was significantly reduced to 
only 19.11 % (p < 0.005) when compared to 
untreated controls.  
 
To investigate the basis of botulin-induced loss of 
cell viability, the levels of apoptotic biomarkers 
were analyzed after betulin treatments. The cells 
exhibited increased caspase-3 activities after 
betulin treatment (Figure 1B), indicating that 
apoptotic signaling was induced. In addition, 
Western blot showed that one of the apoptotic 
biomarkers, poly (ADP-ribose) polymerase 
(PARP), was cleaved 8 h after betulin treatment 
(Figure 1E), suggesting apoptosis was fully 
activated. These results show that betulin 
inhibited SK-N-SH cells survival by inducing 
apoptosis. Furthermore, to verify the specific 
apoptosis pathways that were activated, the 
activities of caspase sub-types were assayed. 
Eight hours post-drug-treatment, caspase-9 
exhibited significantly higher caspase activity (p 
< 0.005, Figure 1C) when compared to caspase-
8 (p < 0.05, Figure 1D). This suggests that 
betulin induced apoptosis via the caspase-9 
pathway. 
 
Effect of butelin on apoptosis pathways  
 
In order to understand the mechanism by which 
betuliin induced apoptosis, the downstream 
pathways of caspase-8 and caspase-9 were 
examined. The results presented in Figure 2 
showed that betulin treatment had no effect on 
extrinsic apoptotic biomarkers (Figure 2D), which 
is consistent with the changes in caspase-8 
activity (Figure 1C). These results show that 
betulin does not activate the extrinsic pathway of 
apoptosis. 
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Figure 1: Effect of betulin on cell viability and apoptotic biomarkers. (A) SK-N-SH cells were treated with different 
concentrations of betulin (0, 2.5, 5, 7.5, 10, 12.5 and 15μM) for 48 h, and cell viability was quantified using MTT 
assay. (B-D) Time course analysis of caspase-3 (B), 8 (C) and 9 (D) activity following 15μM betulin treatment for 
indicated periods (0,2, 4, 8 h). Protein sample (50 μg) was used to verify the changes in caspase activities. (E) 
Western blot analysis of PARP cleavage. SK-N-SH cells were treated with 15μM betulin for indicated periods, 
and 50 μg protein of cell lysates were resolved by SDS-PAGE. The cleaved PARP was detected using rabbit 
anti-PARP (1:5000) and anti-rabbit HRP (1:3000); (*p < 0.05, **p < 0.01, ***p < 0.005) 
 
In contrast to the extrinsic pathway, caspase-9 
activity increased dramatically following betulin 
treatments (Figures 2A, 2B). However, when 
apoptosis was inhibited, caspase-9 activity was 
decreased significantly, suggesting that caspase-
9 was activated after betulin treatment. Betulin 
treatment showed no significant effects on Bax, 
Bak, Smac and cytochrome C expression levels 
(Figure 2C), yet it promoted the translocation of 
these biomarkers. Results showed that betulin 
treatment led to the release of Smac and 
cytochrome C from mitochondria into the cytosol 
(Figure 2B), while Bax and Bak were 
accumulated in mitochondria (Figure 2A). 
 
Effect of PKC in betulin-induced apoptosis 
 
PKC activity was changed in cells treated with 
betulin (Figure 3A). To further confirm the 
relationship between activation of apoptotic 
signaling and PKC activation, caspase inhibitor 
Z-VAD-FMK was used. Combined treatment with 
Z-VAD-FMK and betulin significantly inhibited 
caspase-3 activity (Figure 3B), indicating that 
betulin treatment activated apoptotic signaling in 
a caspase-dependent manner. Interestingly, in 
this study, it was found that Z-VAD-FMK had little 
effects on PKC activation (Figure 3C), which 
indicates that PKC might be one of the upstream 
factors involved in betulin-induced apoptosis. 
 
To investigate if PKC was essential for betulin-
induced apoptosis, caspase-3 and caspase-9 
activities were assayed with and without 
GF109203X treatment. Co-treatment with 
GF109203X and betulin significantly decreased 
caspase-3 (Figure 3D) and caspase-9 (Figure 
3E) (p<0.005) activities in SK-N-SH cells, 
resulting in the total inhibition of apoptosis. 
 
In order to ascertain if PKC could inhibit the 
release of apoptotic factors, the extent to which 
the proteins involved in caspase-9 pathways 
were expressed was analyzed. Immunoblot 
results showed that in cells treated with betulin 
and GF109203X, signal factors such as Smac  
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Figure 2: Effect of betulin on activation of intrinsic or extrinsic apoptotic pathways. SK-N-SH cells were treated 
with 15 μM betulin for the time period indicated. (A) mitochondrial fraction; (B) cytosol fraction; (C) total cell 
lysates; (D) caspase-8 down-stream proteins (CD95, TNF-R2, DR5 and DR4) were resolved by SDS-PAGE to 
verify protein expressions, using rabbit anti-Bax (1 :1000), rabbit anti-Bak (1:1000), rabbit anti-Smac (1:8000), 
mouse anti-Cyto C (1:2000), rabbit anti-COX IV (1:2000), and mouse anti β-actin (1:5000) with secondary anti-
rabbit HRP (1:3000) and anti-mouse HRP (1:4000) 
 
and Cyto C were still released into the cytosol 
fraction (Figure 3F) and translocations of Bax 
and Bak were also detectable. However, 
caspase-3/9 and PARP activities were not 
activated (Figure 3G). Evidently PKC had no 
effects on translocation and release of apoptotic 
factors but could inhibit the activation of caspase-
9. 
 
Role of PKC-δ in butelin-mediated apoptosis 
 
Neither PMA nor GF109203X exhibited 
perceptible impacts on cell viability. However, in 
the combined treatment with betulin, cell viability 
significantly increased in the presence of 
GF109203X (Figure 4A; p<0.05). In contrast to 
GF109203X, cell viability was significantly 
reduced (p<0.01) in the co-treatment cases 
involving PMA and betulin, indicating that PKC 
activation was critical for SK-N-SH survival. 
 
Having established that PKC activity was critical 
for SK-N-SH survival, attempt was made to find 
out the PKC sub-types involved in betulin-
induced apoptosis. For this purpose, western 
blotting was performed using specific antibodies 
(Figure 4B). The results showed that there were 
no changes in the levels of PKC-α and PKC-ζ 
expressions after betulin treatment, but PKC-δ 
expression was increased, which was consistent 
with the finding that PKC activity was reduced 
when GF109203X was introduced. To confirm if 
PKC-δ played an important role in cell survival, 
cells were transfected with the activated form of 
PKC-δ (PKC-δ-CF). SK-N-SH cells over 
expressing PKC-δ-CF, on treatment with betulin, 
had significantly reduced viability when 
compared to betulin-treated untransfected cells 
(p < 0.01). Treatment with PKC inhibitors 
diminished this effect. 
 
PKC-δ knockdown significantly decreased the 
apoptosis-inducing effect of betulin in SK-N-SH 
cells (figure 4C; p<0.01). PMA treatments 
showed little effects on cell viability in the PKC-δ 
knockdown cells. 
 
However, in combined treatments with PKC-δ-
CF, it was obvious that overexpression restored 
betulin-mediated damages. This is an indication  
Feng et al 




Figure 3: Effects of combined betulin and Z-VAD-FMK or GF109203XC treatments on apoptosis. (A) PKC 
activities in cells treated with 15 μM betulin for the periods indicated were quantified using ELISA. (B-C) SK-N-SH 
cells were treated with 15 μM betulin and/or 10 uM Z-VAD-FMK for 4 h. Caspase-3/9 activities (B) and PKC 
activities (C) of the treated and untreated cells were assayed. (D-G) SK-N-SH cells were treated with 15 μM 
betulin and/or 4 μM GF109203XC for 4 h. Caspase-3 (D) and caspase-9 (E) activities of treated or untreated cells 
were quantified. Cell lysates were further resolved by SDS-PAGE to verify the changes in protein expression in 
mitochondrial and cytosol fraction (F) or in total cell lysates (G) using rabbit anti-Bax (1 :1000), rabbit anti-Bak 
(1:1000), rabbit anti-Smac (1:8000), mouse anti-Cyto C (1:2000), rabbit anti-PARP (1:5000) secondary anti-rabbit 
HRP (1:3000) and anti-mouse HRP (1:4000). (***p < 0.005) 
 
that PKC-δ played a significant role in betulin-
induced apoptosis. These results revealed that 
betulin treatment activated PKC-δ which 
subsequently activated intrinsic apoptosis 





Neuroblastoma is a type of nerve tissue cancer 
which commonly occurs in infants and young 
children (0-14 years old), and accounts for 15% 
of childhood death due to tumor. It is difficult to 
diagnose at early stages. Neuroblastoma is 
highly heterogeneous because of its complicated 
genetic backgrounds, clinical symptoms and 
pathogenic stages [2,4,6]. For high-risk patients 
or patients at late stage, it is difficult to arrest the 
disease progression even with increased doses 
of the drugs in extant use for its management 
and/ or treatment. Currently, chemotherapy is still 
the primary approach for treating neuroblastoma 
although drug resistance might result in the 
failure of chemotherapy. Drug resistance is an 
adopted defense system by which tumor cells 
survive drug treatment. 
 
The hypothesis on which this study was based 
was that changes in certain biological 
characteristics of NB in high-risk patients have 
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allowed the tumor to evade synthetic drugs, thus 
making it difficult to treat. Drug resistance occurs 
due to PKC activity and its subcellular 
translocation, as well as abnormal inhibition of 
apoptosis [25].The present study shows that 
betulin regulates the activity of PKC, the enzyme 
which initiates apoptosis in SK-N-SH cells 
 
Figure 4: Effect of betulin on PKC-mediated cell 
death. (A) SK-N-SH cells were treated with 8 μM 
betulin, 100nM PMA and/or 2μM GF109203XC for 48h 
as indicated, and cell viability was quantified using 
MTT assay. (B) Immuno-blot analysis of PKC. Cells 
treated with/without betulin were lysed and resolved by 
SDS-PAGE to analyze the expression of PKCα, PKCδ 
and PKCζ using rabbit anti-PKC-α (1:1000), mouse 
anti-PKC-ζ (1:800), rabbit anti-PKC-δ (1:1000) and 
relevant secondary HRP antibodies. (C) 24 h post-
transfection, SK-N-SH cells transiently over-
expressing PKCδ and PKCδ knockdown cells were 
treated with 8 μM betulin, 100nM PMA and 2μM 
GF109203XC for 48 h, followed by MTT assay to 
verify cell viability in the presence of the drug;   (*p < 
0.05, **p < 0.01) 
This study has demonstrated that betulin-induced 
apoptosis was mediated by mitochondria-linked 
endogenous pathways. During the caspase-9-
dependent apoptotic process, Smac and 
cytochrome C were released into cytoplasm, 
while Bax and Bak accumulated in mitochondria. 
Yet, there were no significant changes in the 
expression of the apoptotic proteins. Bax and 
Bak translocation promoted the permeability of 
mitochondrial membrane to released pro-
apoptotic factors, and activated caspase-3 [26], 
which initiated  apoptosis. This suggests that 
betulin possesses anti-tumor potential, which 
should be further investigated in animal 
experiments and clinic trials. 
 
In view of the apoptosis-inducing ability of 
betulin, the mechanism underlying its apoptotic 
activity was investigated. It was discovered that 
betulin treatment significantly increased PKC 
activity. When PKC was inhibited, cell viability 
was significantly increased, indicating that PKC 
participated in betulin-induced apoptosis. PKC is 
a class of phosphokinases that plays prominent 
roles in cell differentiation, migration, 
proliferation, and apoptosis [27]. Cells treated 
with both PKC inhibitor and betulin had lower 
caspase-9 activity, and PARP cleavage was also 
effectively inhibited. Thus, PKC plays an 
important role in the regulation of SK-N-SH cells 
apoptosis induced by Betulin.   
 
Although PKC has been recognized as one of 
the important targets for tumor drugs as early as 
2010, the clinical effects of PKC manipulation 
was not promising. Here, evidence is provided   
that PKC plays a key role in betulin-induced 
apoptosis, and that simply activating or inhibiting 
the activity PKC has no impact on tumor viability. 
This finding might partially explain why drugs 
targeting PKC have so far produced no anti-
cancer effects. In this betulin-induced apoptosis 
system, it was observed that due to butelin 
treatment PKC and caspase-9 were thereby 
triggering on apoptosis in SK-N-SH cells. 
Furthermore, it was discovered that PKC-δ was 
the activated member of the PKC sub-family 
during the apoptotic process. Therefore, it was 
analyzed in order to understand its role in 
betulin-induced apoptosis of SK-N-SH cells. 
Using a PKC-δ-CF construct, the effect of PKC-δ 
over-expression on apoptosis in the presence of 
the drug was analyzed. MTT assay showed that 
the sensitivity of SK-N-SH cells to betulin was 
up-regulated when PKC-δ was over-expressed, 
while knockdown of PKC-δ in SK-N-SH cells 
significantly increased the cell survival, even 
under the treatment of PMA. This suggests that 
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PKC-δ is one of the main subtypes of PKC 
involved in betulin-mediated apoptosis. 
 
In this study, the hypothesis was that in betulin-
induced apoptosis, signaling factors such as Bax 
and Bak were translocated to mitochondria, 
increasing the permeability of the mitochondrial 
membrane, thus enhancing the release of 
apoptotic related factors into the cytoplasm. 
These pro-apoptotic factors activated caspase-9, 
and subsequently caspase-3, thereby initiating 
apoptosis. For cancer therapy, researchers aim 
to overcome drug resistance. Extensive studies 
have been carried out, yet the drugs continue to 
exhibit limited efficacy against cancer cells. As a 
natural drug, betulin has been reported to 
regulate signal transduction, and promote 
apoptosis with little side effects in a cell model 
[13]. Based on the findings in this study it can be 
speculated that betulin can be utilized as a 
complementary drug to induce programmed 




This study provides bases for better 
understanding of the mechanism of NB 
proliferation as well as focused strategy for 
meaningful management and ultimate treatment 
of neuroblastoma. Betulin could be a promising 
natural agent against cancer that should be 
considered for future pre-clinical and clinical trials 
from the perspective of adjuvant chemotherapy 
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